Wendy's Poison Pill: Trian's $7.35 Offer and the 15% Rights Plan
Some links pay us a referral fee; each one says so. Disclosure
Filing alert · free
An email when The Wendy's Company files with the SEC
An email the day The Wendy's Company files something new, with the link to the document on the SEC site.
Quick Answer
On October 28, 2026 a group led by Trian Fund Management offered $7.35 a share in cash for the Wendy's shares it does not own; on November 5, 2026 Wendy's independent committee unanimously rejected it and the board announced a one-year rights plan, a “poison pill,” that makes crossing 15% very costly for any buyer the board has not approved. The offer comes from Trian, Flynn Group, BlueFive Capital and Sixth Street Partners. Trian and its affiliates held 30,979,420 shares, 16.25%, on October 27, 2026, so the 15% trigger starts below where they already stand; the plan's grandfathering clause lets a holder that was already above 15% keep its stake, but treats any further share it buys as a trigger. Each right, once triggered, lets every other holder pay $37.00 for $74.00 of stock, or the board can swap each right for one common share. The rights expire on November 3, 2027. Wendy's says the offer “substantially undervalues the Company.” By our arithmetic the offer values all 194.0 million fully diluted shares at about $1.43 billion, and the shares Trian does not own at about $1.18 billion. As of November 15, 2026 the last filing on EDGAR is dated November 5, 2026.
Key Takeaways
- Trian's letter of October 28, 2026 proposes $7.35 per share in cash, about a 20% premium to the October 27, 2026 close, for a merger needing approval by a majority of the outstanding shares, with Trian rolling over its own shares and no financing condition or new debt.
- The board (without the directors affiliated with Trian) adopted the Rights Agreement on November 4, 2026: one right per share, record date November 16, 2026, trigger at 15%, exercise price $37.00 per one one-thousandth of a preferred share, redemption price $0.001 per right, expiration November 3, 2027.
- Trian's group reported 30,979,420 shares (16.25%) in its October 28, 2026 Schedule 13D/A. That is above the 15% line, so under the plan's grandfathering definition it can keep the stake but any additional share it buys would make it an Acquiring Person.
- Trian's share count has been flat for two years (31,025,929 in August 2024, 30,979,420 in October 2026) while shares outstanding fell from 203,242,708 to 190,669,930; the percentage rose from 15.27% to 16.25% without new purchases (our arithmetic).
- Wendy's own April 2, 2026 proxy statement listed “No stockholder rights plan or ‘poison pill.’” as a governance feature; the plan was adopted seven months later, and the same board meeting also removed the Trian-founders exclusion from the equity plans' definition of Change in Control.
- In the quarter ended September 27, 2026 Wendy's earned $15.1 million against $44.3 million a year earlier, paid a $0.07 dividend against $0.14 and carried $2,712.7 million of long-term debt; Trian's letter points to “approaching debt maturities” and the committee points to a plan called Dave's Way.
CSV · 78 rows
Wendy's, Trian and the 2026 rights plan: proposal, plan terms, stake history, board response, Q3 2026 10-Q
78 rows from Wendy's November 5, 2026 8-K and Rights Agreement, the October 28, 2026 Schedule 13D/A with the proposal letter, the three earlier 13D/A amendments, the Q3 2026 10-Q and the 2024 and 2026 proxy statements, with the accession number on every row.
The story, with dates
Wendy's earns most of its income from franchisees: of the $8,355.8 million of U.S. systemwide sales in the first nine months of 2026, $7,673.6 million were at franchised restaurants. For about 17 years its non-executive Chairman was Nelson Peltz, co-founder of Trian. He left the board in September 2024 but a Trian partner stayed on it. In February 2026 Trian told the SEC it was talking to financing sources, co-investors and strategic partners about transactions that “may benefit the Company's shareholders.” Eight months later it put a number on the table.
| Date | Event | Source |
|---|---|---|
| June 2007 | Nelson Peltz becomes non-executive Chairman (he had been Chairman and CEO since April 1993) | 2024 proxy statement |
| September 6, 2024 | Peltz resigns from the board and is named Chairman Emeritus; Arthur Winkleblack becomes Chairman | 8-K, Item 5.02 |
| July 8, 2025 | A second Peltz family director leaves the board and another family member is elected in his place | 8-K, Item 5.02 |
| February 18, 2026 | Trian's Schedule 13D/A (Amendment 64) says it has spoken with potential financing sources, co-investors and strategic partners; stake 31,078,148 shares, 16.33% | Schedule 13D/A |
| April 2, 2026 | Proxy statement lists “No stockholder rights plan or ‘poison pill.’” among Wendy's governance features | DEF 14A |
| October 28, 2026 | Trian, Flynn Group, BlueFive Capital and Sixth Street Partners send a $7.35 per share proposal and file Schedule 13D/A Amendment 65 | Schedule 13D/A |
| November 4, 2026 | Board, without the Trian-affiliated directors, adopts the Rights Agreement and amends the equity plans and severance policy | 8-K, Items 1.01, 3.03, 5.02, 5.03 |
| November 5, 2026 | Independent committee rejects the proposal; press release, 8-K, Form 8-A12B and third-quarter 10-Q are filed | 8-K, Exhibit 99.1; 10-Q |
| November 16, 2026 | Record date: every common shareholder gets one right per share | 8-K, Item 1.01 |
| November 3, 2027 | Rights expire at the close of business unless redeemed or exchanged first | Rights Agreement, Section 7(a) |
What the Rights Agreement says, term by term
The 8-K summarizes the plan and attaches the full agreement as Exhibit 4.1. The table below is read from both.
| Term | What the filing says | Where |
|---|---|---|
| Trigger | 15% or more of the common shares, counting economic exposure through certain derivatives, without approval of the board or the independent committee | 8-K Item 1.01; press release |
| Who the board is | The board excluding the directors affiliated with Trian adopted it on November 4, 2026 | 8-K Item 1.01 |
| Rights issued | One right per common share held at the close of business on November 16, 2026 | 8-K Item 1.01 |
| Exercise price | $37.00 per one one-thousandth of a share of Series A Junior Participating Preferred Stock | 8-K Item 1.01 |
| Flip-in | After a person crosses the trigger, every other holder can pay the purchase price and receive common shares worth twice that price; the triggering person's rights become void | 8-K Item 1.01 |
| Flip-over | If the company later merges away or sells 50% or more of its assets or earning power, holders can buy the acquirer's stock worth twice the purchase price | 8-K Item 1.01 |
| Exchange | The board can swap each right for one common share at any time after a person becomes an Acquiring Person and before that person owns 50% or more | Rights Agreement, Section 24(a) |
| Redemption | The board can redeem all rights for $0.001 each at any time before a person becomes an Acquiring Person | Rights Agreement, Section 23(a) |
| Grandfathering | A holder already at 15% or more when the plan is first announced is not an Acquiring Person, but becomes one if it acquires any additional common shares (compensation grants approved by the board, stock splits and dividends excepted); grandfathering ends on the first fall below 15% | Rights Agreement, Section 1(u) |
| Acting in concert | Shareholders “acting in concert” are not aggregated until they have formed a group under securities laws | Press release |
| Dead-hand features | The press release says the plan has no dead-hand, slow-hand or no-hand feature limiting a future board's ability to redeem the rights | Press release |
| Expiration | November 3, 2027, a one-year plan | Rights Agreement, Section 7(a) |
Two details matter more than the headline 15%. First, until the Distribution Date the rights ride on the common shares and cannot be traded separately, and a right holder as such has no vote and no dividend. Second, the plan did not go to a shareholder vote: the filing says the board adopted it, and nothing in the 8-K or the agreement makes it depend on one.
How a poison pill dilutes a buyer, with the plan's own numbers
The pill never has to be exercised to work; it only has to be credible. The two ways it could hit a buyer who crosses 15% without the board's approval are below. We use Wendy's 191,242,899 shares outstanding on October 29, 2026 and Trian's 30,979,420 shares, only as an illustration of mechanics; this is not a forecast that Trian will trigger the plan.
| Step (our arithmetic) | Number | How it is built |
|---|---|---|
| Trian group stake on 191,242,899 shares | 16.20% | 30,979,420 divided by 191,242,899 |
| Shares that equal 15% | 28,686,435 | 191,242,899 times 0.15; Trian is about 2.29 million shares above it |
| Rights held by everyone else | 160,263,479 | 191,242,899 minus 30,979,420, one right per share (assumes the November 16, 2026 count equals the October 29, 2026 count) |
| If the board exchanges each right for one common share | 351,506,378 shares outstanding afterward | 191,242,899 plus 160,263,479 |
| Trian group stake after that exchange | 8.81% | 30,979,420 divided by 351,506,378: a stake that was 16.20% is cut nearly in half, with no cash paid by anyone |
| If instead holders exercise with the stock at $6.125 | 12.08 shares per right | $74.00 of stock for $37.00; $6.125 is $7.35 divided by 1.20, the price implied by the letter's roughly 20% premium, used only as an example |
| Trian group stake after that exercise | about 1.46% | 30,979,420 divided by (191,242,899 plus 160,263,479 times 12.08) |
The point of the second row of numbers is the shape, not the decimals: a stake of about 16% becomes a stake of 1% to 9% depending on how the rights are used, while every other holder keeps the same percentage of what is left. That is what “imposing significant dilution” means in the 8-K, and it is why a bidder generally negotiates with the board instead of buying shares in the open market.
Trian's stake over time
| As of | Shares reported | Percent of class | Shares outstanding used | Filing |
|---|---|---|---|---|
| August 8, 2024 | 31,025,929 | 15.27% | 203,242,708 | 13D/A Amendment 61 |
| July 7, 2025 | 31,069,149 | 16.18% | 192,025,248 | 13D/A Amendment 63 |
| February 17, 2026 | 31,078,148 | 16.33% | 190,339,781 | 13D/A Amendment 64 |
| October 27, 2026 | 30,979,420 | 16.25% | 190,669,930 | 13D/A Amendment 65 |
The group's share count has barely moved: 46,509 fewer shares in October 2026 than in August 2024 (our arithmetic), while Wendy's retired 12,572,778 shares over the same period, 6.2% of the 2024 count. Almost all of the rise from 15.27% to 16.25% is the denominator shrinking. In October 2026 the largest pieces were the funds managed by Trian Fund Management, which together held 14,943,466 shares, 7.84%; the rest is held by the two founders, family entities and foundations as listed in the filing.
Trian has also had room above 15% for years: Wendy's proxy statement says that under a December 1, 2011 agreement its board approved Trian and its covered persons owning up to 32.5% of the shares for purposes of Section 203 of the Delaware General Corporation Law. The rights plan is a separate mechanism with a lower line, 15%.
What the documents show that the headlines don't
- The “$1.4 billion” depends on which shares you count. The letter assumes 194.0 million fully diluted shares (190.7 million common plus 3.3 million restricted units; 12.0 million options struck at an average $15.57 are out of the money at $7.35). At $7.35 that is $1,425.9 million for everything, but Trian is rolling its own shares, so cash to everyone else is about $1,177.9 million on the 191,242,899 shares outstanding less Trian's 30,979,420 (our arithmetic).
- Trian is already above the trigger. The plan does not push Trian down; it freezes it. The 15% line cannot be crossed by buying; the plan's grandfathering clause is aimed at exactly a holder in Trian's position, although neither the 8-K nor the agreement names Trian as grandfathered, so that is our reading of the definition against the October 28, 2026 numbers.
- The plan and the equity amendments were adopted together. The same November 4, 2026 meeting approved amendments to the 2010 and 2020 equity plans and the executive severance policy: the Change in Control definition no longer excludes transactions involving Trian's founders or entities they control, performance units convert to restricted stock units on a Change in Control, and an 18-month protection period applies to resignations for “Good Reason.” The 8-K lists these under Item 5.02.
- The cooperation letter locks the buyers together for a year. In Exhibit 47 to the 13D/A, Trian and Flynn agree to work exclusively with each other on a transaction for 12 months, and the 13D/A says the letter bars Flynn from acquiring shares or economic exposure in Wendy's while it is in force. Whether that makes Flynn part of a 13(d) group is a legal question the filings do not answer.
- The board says it offered a standstill first. The 8-K says the board considered that “the Investor Group rejected an offer from the Company to enter into a customary standstill agreement.” Trian's filings do not discuss it.
- The April 2026 proxy said no pill. Wendy's April 2, 2026 proxy statement listed “No stockholder rights plan or ‘poison pill.’” first among a set of governance features that also included written consent and the ability to call special meetings. The plan came seven months later.
Both sides, in their own words
| Trian-led group (letter of October 28, 2026) | Wendy's independent committee (press release of November 5, 2026) | |
|---|---|---|
| On value | Offers a premium of about 20% to the October 27, 2026 close and “certain, premium value, free from the risks associated with a complex multi-year transformation in a challenging environment” | Concludes the proposal “substantially undervalues the Company” and “is not in the best interests of Wendy's and its shareholders” |
| On the business | Says the business needs “significant capital investment to de-lever” and points to “approaching debt maturities” | Points to Dave's Way, a plan announced the same day, built on five pillars and led by the current CEO |
| On the rights plan | Not addressed in the letter (filed before the plan existed) | Intended “to reduce the likelihood that any person or group gains actual or negative control of the Company without paying all shareholders an appropriate premium for that control” |
| On what happens next | Says it is “highly confident” it can negotiate definitive agreements “over the coming weeks” | Says it “does not intend to comment further on this matter unless it determines that additional disclosure is appropriate or required” |
What this means for your money
The Wendy's story is useful to a reader who owns anything with a board, because it separates four things that get mixed up.
Who controls the vote. A merger at $7.35 needs a majority of the outstanding shares, the letter says. On 191,242,899 shares a majority is 95,621,450. If Trian's 30,979,420 shares vote yes, it needs 64,642,030 more, about 40.3% of the other 160,263,479 shares (our arithmetic). That is a different bar from the board's own, which decides whether there is a merger agreement to vote on. Nothing in the filings gives a holder a way to make the board sign one; a holder can vote, and the 2026 proxy statement says stockholders can act by written consent and call special meetings. Compare how control is split in Anthropic's S-1, where one share carries 50.1% of the votes, and what a court said holders could and could not demand in Dodge v. Ford.
Price against what the company owns. Wendy's earns franchise royalties, fees and rental income; how McDonald's makes money from real estate shows how to read that mix in a 10-K. A bid is a price for those cash flows, set against $2,712.7 million of long-term debt and net income of $70.4 million for nine months in 2026 against $138.6 million a year earlier. The 10-Q is where to check both sides' claims about debt and earnings.
What a pill can and cannot do. It does not stop a deal the board approves; it raises the cost of buying around the board. In the 8-K the board describes it as meant “to ensure that all stockholders receive fair and equal treatment”; Trian's filings do not comment on the plan. The plan is one year long and the board can redeem it for $0.001 a right.
Cash that comes off the top. The dividend fell to $0.07 in the third quarter of 2026 from $0.14, and the equity plans now pay out faster on a Change in Control. Those are filed facts; whether either belongs in a price is for the holder.
What a reader can do with this
- Open the November 5, 2026 8-K and Exhibit 4.1, find the trigger, the exercise price, the grandfathering definition and the expiration, and check them against any summary you read.
- Check Wendy's EDGAR page for a new 13D/A, a DEFA14A or an 8-K reporting a revised proposal, a redemption of the rights or a lawsuit. A change of terms appears there first.
- If you hold a listed company or a non-traded REIT, look in its latest proxy statement and charter for rights plans, who can call a meeting and what vote a merger needs; this takes ten minutes and tells you who actually decides.
- For anything you own through a fund, read how the manager is paid on a sale; a buyout changes who gets paid first.
This is analysis of public documents, not investment, legal or tax advice.
FAQ
Sources, read on November 15, 2026: The Wendy's Company (CIK 30697) Form 8-K of November 5, 2026 (accession 0001193125-26-448576) with Exhibit 4.1 Rights Agreement dated as of November 4, 2026, Exhibit 3.1 and Exhibit 99.1 press release; Form 8-A12B of November 5, 2026 (0001193125-26-448603); Form 10-Q for the quarter ended September 27, 2026 (0000030697-26-000179); Form 8-Ks of September 6, 2024 (0001193125-24-215257) and July 8, 2025 (0001193125-25-156450); proxy statements of April 4, 2024 (0001193125-24-087279) and April 2, 2026 (0001193125-26-140220); and Trian Fund Management's Schedule 13D/A Amendments 61 (0000950170-24-095003), 63 (0000950170-25-094459), 64 (0001193125-26-056159) and 65 (0000930413-26-003164) with the October 28, 2026 proposal letter (Exhibit 46) and the cooperation letter between Trian and Flynn Group (Exhibit 47). Aggregate offer values, the dilution examples, the majority vote count and the change in Trian's share count are our arithmetic from those figures; the $6.125 example price is derived from the letter's approximate 20% premium and is not a quoted price. This is analysis of public documents, not investment, legal or tax advice.
Keep reading.
- 0118 min read
Average Down Payment on a House: What 2.77 Million Buyers Put Down
Median down payment on a house in 2025 federal data: 10% and $30,000 on 2.77 million loans, by loan type, age and state, plus a $385,000 payment example.
- 0218 min read
Chattel Loan Rates 2025: Home-Only Loans Had a 9.47% Median Rate, 6.75% With Land
2025 HMDA data on 127,410 manufactured-home purchase loans: home-only (chattel-type) loans had a 9.47% median rate and 74.1% denial rate, home-and-land 6.75%.
- 0318 min read
Credit Union Mortgage Lenders Ranked, 2025: Navy Federal 80,547
2025 HMDA: Navy Federal made 80,547 loans; credit unions' median rate 6.5%, total costs $3,871 vs $6,199 at non-banks, but 17.3% denied. Top 25 ranked.